TechVision Fonds I invests in PL BioScience
The TechVision Fonds brings in new capital in PL BioScience
The TechVision Fonds, managed by the S-UBG group, supports innovative start-up businesses with capital, expertise and know-how. They provide a strong network of national and international investors.
Convincing human Platelet Lysate (hPL) technology and quality
Our vision of a cruelty- and animal-free cell culture future and our business model convinced the investors.
HPL can effectively replace Fetal Bovine Serum (FBS) as an animal-free cell culture supplement. It even shows enhanced cell growth, is morally inoffensive and GMP conform (Good Manufacturing Practice).
25% market growth in regenerative medicine
Bernhard Kugel, CEO of management corporation, states that there will be an increasing need for cell culture media in the next five years. This is due to the predicted market growth of 25% in regenerative medicine by the research company Fortune Business Insights.
Our aim is to become a technological leader
We already performed a successful market entry and obtain significant turnover in research, biotech and life science areas.
We want to rise PL BioScience as technological leader for human Platelet Lysate and cell culture technology. Our cell culture supplements provide a solution for every phase of stem cell research and development.
We use the capital for product development, sales and distribution
With the platelet-based technology we will offer several product variations. We will now push these product developments and productions.
Our goal is finalising our technology and expanding our production, sales and distribution.
Read the whole press release here
Get to know our product portfolio
Source: TechVision Fonds